open access

Vol 13, No 1 (2019)
Case report
Published online: 2019-04-04
Get Citation

Pharmacological treatment of hemoptysis in a patient diagnosed with lung tumor and chronic atrial fibrillation

Rafał Suchodolski, Karol Wierzba
DOI: 10.5603/PMPI.2019.0006
·
Palliat Med Pract 2019;13(1):35-38.

open access

Vol 13, No 1 (2019)
Case report
Published online: 2019-04-04

Abstract

W artykule przedstawiono skuteczne i dobrze tolerowane leczenie farmakologiczne krwioplucia u 95-letniego pacjenta z rozpoznaniem guza płuca. W pracy omówiono wyzwania terapii związane z wielochorobowością i inne możliwości leczenia krwioplucia. Palliat Med Pract 2019; 13, 1: 35–38

Abstract

W artykule przedstawiono skuteczne i dobrze tolerowane leczenie farmakologiczne krwioplucia u 95-letniego pacjenta z rozpoznaniem guza płuca. W pracy omówiono wyzwania terapii związane z wielochorobowością i inne możliwości leczenia krwioplucia. Palliat Med Pract 2019; 13, 1: 35–38

Get Citation

Keywords

kwas traneksamowy, etamsylat, krwioplucie, guz płuc

About this article
Title

Pharmacological treatment of hemoptysis in a patient diagnosed with lung tumor and chronic atrial fibrillation

Journal

Palliative Medicine in Practice

Issue

Vol 13, No 1 (2019)

Pages

35-38

Published online

2019-04-04

DOI

10.5603/PMPI.2019.0006

Bibliographic record

Palliat Med Pract 2019;13(1):35-38.

Keywords

kwas traneksamowy
etamsylat
krwioplucie
guz płuc

Authors

Rafał Suchodolski
Karol Wierzba

References (14)
  1. Garay RP, Chiavaroli C, Hannaert P. Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent. Am J Ther. 2006; 13(3): 236–247.
  2. Ittrich H, Bockhorn M, Klose H, et al. The Diagnosis and Treatment of Hemoptysis. Dtsch Arztebl Int. 2017; 114(21): 371–381.
  3. Lip , et al. See Van den Ham et al.CHADSVASC clinical risk estimation.
  4. Hamilton W, Peters TJ, Round A, et al. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005; 60(12): 1059–1065.
  5. Hu P, Wang G, Cao H, et al. Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection. Br J Cancer. 2013; 109(6): 1609–1617.
  6. Hulme B, Wilcox S. Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the management of bleeding for palliative care patients with cancer, November 2008.
  7. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration. 2010; 80(1): 38–58.
  8. Charakterystyka Produktu Leczniczego, Cyclonamine.
  9. Lewis GJ. Does ethamsylate increase the incidence of venous thrombosis? Br Med J (Clin Res Ed). 1984; 288(6421): 899–900.
  10. Symes DM, Offen DN, Lyttle JA, et al. The effect of dicynene on blood loss during and after transurethral resection of the prostate. Br J Urol. 1975; 47(2): 203–207.
  11. Gadre A, Stoller J. Tranexamic Acid for Hemoptysis. Clinical Pulmonary Medicine. 2017; 24(2): 69–74.
  12. Prutsky G, Domecq JP, Salazar CA, et al. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev. 2016; 11: CD008711.
  13. Calapai G. Systematic Review of Tranexamic Acid Adverse Reactions. Journal of Pharmacovigilance. 2015; 03(04).
  14. Gagnon S, Quigley N, Dutau H, et al. Approach to Hemoptysis in the Modern Era. Can Respir J. 2017; 2017: 1565030.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl